Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%22 Pretax Margin % is 10.26% as of Mar. 2026, which is 53% below its 10-year median of 21.81. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Invicta Diagnostic ranks better than 90.05% on this metric.
The historical rank and industry rank for Invicta Diagnostic's Pretax Margin % or its related term are showing as below:
NSE:INVICTA'
s Pretax Margin % Range Over the Past 10 Years
Min: 21.66 Med: 21.81 Max: 32.35
Current: 21.66
NSE:INVICTA's Pretax Margin % is ranked better than 90.05% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.86
vs NSE:INVICTA: 21.66
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Invicta Diagnostic Pretax Margin % Related Terms
Invicta Diagnostic Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Invicta Diagnostic's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic Pretax Margin % Chart
Invicta Diagnostic Annual Data
Trend
Mar24
Mar25
Mar26
Pretax Margin %
32.35
21.81
21.66
Invicta Diagnostic Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
Pretax Margin %
0.00
0.00
32.03
10.26
NSE:INVICTA vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic (NSE:INVICTA) has a Pretax Margin % of 10.26% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Invicta Diagnostic and its competitors. This is 53% below median its historical median of 21.81. Over the past decade, Invicta Diagnostic's Pretax Margin % has ranged from 21.66 to 32.35. According to the industry distribution chart, Invicta Diagnostic ranks #20 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 10%.
Is Invicta Diagnostic's Pretax Margin % too high?
Invicta Diagnostic's current Pretax Margin % of 10.26% is 53% below median its 10-year median of 21.81. Over the past 10 years, this metric has ranged from a low of 21.66 to a high of 32.35. Based on the distribution chart, Invicta Diagnostic ranks #20 out of 201 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #20 out of 201 companies for Pretax Margin %. This places Invicta Diagnostic in the top 10% of its industry — outperforming the majority of peers. Historically, Invicta Diagnostic's own Pretax Margin % has ranged from 21.66 to 32.35 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Invicta Diagnostic and its competitors. Invicta Diagnostic's current Pretax Margin % is 10.26%, which is 53% below median its own 10-year median of 21.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current Pretax Margin % of 10.26%. The current Pretax Margin % is 10.26%, which is 53% below median its 10-year median of 21.81. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current Pretax Margin % is 10.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
